Hands-on training in quantitative human cell and effect based in vitro bioanalysis for assessing endocrine disrupting compounds (EDCs) Back
You will learn how you can use a panel of standardized stable human and yeast reporter cell lines for rapid screening of hazards of pure chemicals and complex mixtures on multiple adverse outcome pathways (BioDetection Systems & BASF). This includes those pathways prioritized in the current regulatory context of EDC assessment, including interference with estrogen-, androgen-, and thyroid hormone signaling. This will include assessment of metabolic conversions (S9, metabolically competent liver cells - BIOPREDIC ) of EDCs using various approaches and assessment of their effects on steroidogenesis. Furthermore, the participants will integrate in silico read-across predictions (TNO) that can be particularly suited to confirm biological assays and vice-versa. Moreover, they will be presented information on QSAR models and their performance for a number of EDrelated endpoints (DTU). Trainees will learn more about modern robotic and automated high throughput screening using down-scaled 96-wells to 384-wells formats. The chemical activated luciferase (CALUX) assays are available for testing of relevant matrices such as food, blood, urine, mother milk, and many different environmental matrices. All steps needed from extraction, clean-up, cell culture handling, luminometer analysis, and calculations of effect concentrations and toxic equivalents will be presented in state-of-the-art manner following current guidelines (e.g. ISO 17025, OECD TG455-like, ISO 19040-3). Additionally a state-of-the-art open keynote will be presented by Elise Grignard (European Commission, JRC) along with several oral presentations on the current applications in chemicals, mixture toxicity, food, environmental, and public health testing.
Final Agenda is available here.